BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33575262)

  • 1.
    Liberini V; Rampado O; Gallio E; De Santi B; Ceci F; Dionisi B; Thuillier P; Ciuffreda L; Piovesan A; Fioroni F; Versari A; Molinari F; Deandreis D
    Front Med (Lausanne); 2020; 7():601853. PubMed ID: 33575262
    [No Abstract]   [Full Text] [Related]  

  • 2. Relevance of Volumetric Parameters Applied to [
    Urso L; Castello A; Treglia G; Panareo S; Nieri A; Rambaldi I; Caracciolo M; Ortolan N; Uccelli L; Cittanti C; Castellani M; Bartolomei M
    Diagnostics (Basel); 2023 Feb; 13(4):. PubMed ID: 36832093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from
    Thuillier P; Liberini V; Grimaldi S; Rampado O; Gallio E; Santi B; Arvat E; Piovesan A; Filippi R; Abgral R; Molinari F; Deandreis D
    J Nucl Med; 2022 Jul; 63(7):1014-1020. PubMed ID: 34740949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from
    Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C
    BMC Cancer; 2020 Apr; 20(1):326. PubMed ID: 32299391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [
    Laudicella R; Comelli A; Liberini V; Vento A; Stefano A; Spataro A; Crocè L; Baldari S; Bambaci M; Deandreis D; Arico' D; Ippolito M; Gaeta M; Alongi P; Minutoli F; Burger IA; Baldari S
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
    Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
    Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of hitherto unknown brain meningioma detected on
    Parghane RV; Talole S; Basu S
    World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?
    Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H
    Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT.
    Zwirtz K; Hardt J; Acker G; Baur ADJ; Pavel M; Huang K; Brenner W; Prasad V
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745849
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
    Van Binnebeek S; Vanbilloen B; Baete K; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Bogaerts K; Haustermans K; Nackaerts K; Van Cutsem E; Verslype C; Verbruggen A; Deroose CM
    Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients. Correlation of parameters during PRRT.
    Van Binnebeek S; Koole M; Terwinghe C; Baete K; Vanbilloen B; Haustermans K; Clement PM; Bogaerts K; Verbruggen A; Nackaerts K; Van Cutsem E; Verslype C; Mottaghy FM; Deroose CM
    Nuklearmedizin; 2016 Jun; 55(3):104-14. PubMed ID: 27056060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AI-based quantification of whole-body tumour burden on somatostatin receptor PET/CT.
    Gålne A; Enqvist O; Sundlöv A; Valind K; Minarik D; Trägårdh E
    Eur J Hybrid Imaging; 2023 Aug; 7(1):14. PubMed ID: 37544941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT.
    Durmo R; Filice A; Fioroni F; Cervati V; Finocchiaro D; Coruzzi C; Besutti G; Fanello S; Frasoldati A; Versari A
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation-Based Index and
    Pauwels E; Van Binnebeek S; Vandecaveye V; Baete K; Vanbilloen H; Koole M; Mottaghy FM; Haustermans K; Clement PM; Nackaerts K; Van Cutsem E; Verslype C; Deroose CM
    J Nucl Med; 2020 Jul; 61(7):1014-1020. PubMed ID: 31806775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
    Sabet A; Nagarajah J; Dogan AS; Biersack HJ; Sabet A; Guhlke S; Ezziddin S
    EJNMMI Res; 2013 Dec; 3(1):82. PubMed ID: 24369053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity Comparison of
    Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.